Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces …
KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …
LINC01296 promotes proliferation of cutaneous malignant melanoma by regulating miR-324-3p/MAPK1 axis
K Wang, Q Luo, Y Zhang, X Xie, W Cheng… - Aging (Albany …, 2022 - pmc.ncbi.nlm.nih.gov
Objective: To investigate the functions and potential molecular mechanism of LINC01296
regarding the progression of cutaneous malignant melanoma (CMM) by the regulation of …
regarding the progression of cutaneous malignant melanoma (CMM) by the regulation of …
[HTML][HTML] Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines
N Tawfeeq, JMS Lazarte, Y Jin, MD Gregory… - Oncotarget, 2023 - ncbi.nlm.nih.gov
Finding effective therapies against cancers driven by mutant and/or overexpressed
hyperactive G-proteins remains an area of active research. Polyisoprenylated cysteinyl …
hyperactive G-proteins remains an area of active research. Polyisoprenylated cysteinyl …